Trial
NCT02258529
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
Follicular Lymphoma
Intervention
Idelalisib
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-05-14